In our study, the rate of co-occurring mutations in TP53 was significantly lower in early tumor stages than in advanced tumor stages, although the analysis should be considered with caution due to the low detected frequencies of ALK gene rearrangements of 1.2% (7/567) and 2.2% (14/650) in the groups of early and advanced NSCLC, respectively. The gene discussed is TP53; the disease is non-small cell lung carcinoma.